ReviewFrontiers in cell and developmental biology2025
The role of MMPs in intracerebral hemorrhage.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- The Dual Role of VEGF in Intracerebral Haemorrhage: From Pathological Mechanisms to Therapeutic Opportunities.Revista de neurologia · 2026Review
- The Antioxidant and Neuroregenerative Effects of Thymoquinone in a Rat Intracerebral Hemorrhage Model.Biomedicines · 2026Article
- Inhibition of Astrocytic JMJD3 Attenuates Neuroinflammation-Mediated Blood-Brain Barrier Disruption and Improves Functional Recovery After Intracerebral Hemorrhage in Mice.Brain sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intracerebral hemorrhage (ICH) is characterized by the disruption of cerebral vascular integrity, leading to hematoma enlargement, edema formation and physical damage to brain tissue. It has an extremely high disability rate and mortality rate, with mortality rates as high as 50%, imposing considerable physical and economic burdens on patients and their families. Therefore, identifying effective therapeutic targets for ICH has become an urgent issue. In recent years, numerous animal and clinical studies have shown that matrix metalloproteinases (MMPs), particularly MMP-9 and MMP-2, are closely associated with the pathophysiological processes of ICH. During the acute phase of ICH, MMP expression increases, leading to the disruption of the blood-brain barrier (BBB), exacerbating neuroinflammation and cerebral edema. However, in the subacute and chronic phases, MMPs play a crucial role in BBB repair, angiogenesis, and neurological recovery. Therefore, MMPs hold promise as effective therapeutic targets for ICH. This article provides an overview of ICH, the primary structure, classification, regulation, and role of MMPs in the destruction of the BBB, angiogenesis, and neural repair in ICH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.